United Therapeutics Corporation reported $3.15B of revenue over the trailing twelve months, +2.5% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.15B (to Q2 2026). Net income: $1.31B, trailing twelve months to Q2 2026. Free cash flow: $1.09B, trailing twelve months to Q2 2026. Operating margin: 44%, trailing twelve months to Q2 2026.

UTHRUnited Therapeutics Corporation

Healthcare

$549.48+32% 1Y

$549.48

$414.7352 weeks$596.76

UTHR as reported

United Therapeutics Corporation reported $3.15B of revenue over the trailing twelve months, +2.5% on the year before. 11 reported series are charted on this page, each one as filed.

$3.15B

Revenue, trailing twelve months · to Q2 2026 · +2.5% against the twelve months before

Net income: $1.31B
Net income · +5.5% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.09B
Free cash flow · +2.1% year on year · trailing twelve months to Q2 2026
Operating margin: 44%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for UTHR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.15B	+2.5%	Q2 2026
Net income	$1.31B	+5.5%	Q2 2026
EPS	$27.94	+9.0%	Q2 2026
Gross margin	86%	n/a	Q2 2026
Operating margin	44%	n/a	Q2 2026
Net margin	42%	n/a	Q2 2026
ROE	20%	n/a	Q2 2026
ROA	18%	n/a	Q2 2026
ROIC	29%	n/a	Q4 2025
Free cash flow	$1.09B	+2.1%	Q2 2026
P/E	19.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.